Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

Rhea-AI Summary

Celcuity (NASDAQ:CELC), a clinical-stage biotechnology company focused on targeted oncology therapies, has scheduled a conference call and webcast for July 28, 2025, at 8:00 AM ET to present topline results from the PIK3CA Wild-Type Cohort of their Phase 3 VIKTORIA-1 trial in HR+/HER2- advanced breast cancer.

The management team will host the presentation with a live webcast available, and participants can register for the teleconference in advance. A replay will be accessible on Celcuity's website after the event.

MINNEAPOLIS, July 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the Company will hold a conference call and webcast on Monday, July 28, 2025 at 8:00 AM ET to disclose the topline results of the PIK3CA Wild-Type Cohort from the Phase 3 VIKTORIA-1 trial.

Webcast and Conference Call Information

The Celcuity management team will host a webcast/conference call on Monday, July 28, 2025 at 8:00 a.m. ET to discuss the topline results from the Phase 3 VIKTORIA-1 trial. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. A replay of the webcast will be available on the Celcuity website following the live event.

About Celcuity

Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.  A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.

View source version of release on GlobeNewswire.com

Contacts: 

Celcuity Inc. 
Brian Sullivan, bsullivan@celcuity.com 
Vicky Hahne, vhahne@celcuity.com 
(763) 392-0123 

ICR Healthcare
Patti Bank, patti.bank@icrhealthcare.com 
(415) 513-1284

FAQ

When will Celcuity (CELC) announce the VIKTORIA-1 Phase 3 trial results?

Celcuity will announce the topline results on Monday, July 28, 2025, at 8:00 AM ET via a conference call and webcast.

What is the VIKTORIA-1 trial studying for Celcuity (CELC)?

The VIKTORIA-1 trial is a Phase 3 study focusing on HR+/HER2- advanced breast cancer, specifically examining the PIK3CA Wild-Type Cohort.

How can investors access Celcuity's VIKTORIA-1 trial results presentation?

Investors can access the results through a live webcast or register for the teleconference in advance. A replay will be available on Celcuity's website after the event.

What type of breast cancer is being targeted in Celcuity's VIKTORIA-1 trial?

The VIKTORIA-1 trial is targeting HR+/HER2- advanced breast cancer, specifically studying the PIK3CA Wild-Type Cohort.